Electronic Supplementary Information

Catalytic asymmetric aminolactonization of 1,2-disubstitued alkenoic acid esters: Efficient construction of aminolactones with all carbons quaternary stereo-centre

Saumen Hajra,* Sk Md Samim Akhtar and Sk Mohammad Aziz

Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur, India

Experimental Section

A)	General	S2
B)	General procedure for the preparation of 4-arylbut-3-enoic acid	S 2
C)	General procedure for the preparation of tert-butyl 4-arylbut-3-enoate	S 3
D)	General procedure for the preparation of (E)-tert-butyl 5-arylpent-4-enoate	S 3
E)	General Procedure for one-pot enantioselective Synthesis of	
	N-nosyl-4-amino-5-arylbutyrolactones and N-nosyl-5-amino-6-	
	arylvalerolactones (3a-i, 10, 7a-d and 13a-d)	S4
F)	Spectral Data of N-nosyl-4-amino-5-arylbutyrolactones and	
	N-nosyl-5-amino-6-arylvalerolactones (3a-i, 10, 7a-d and 13a-d)	S4
G)	Spectral Data of alkenoic acid esters (1a-i, 8, 5a-d, 11a-d and 1a')	S 10
H)	Synthesis and Spectral Data of compounds 14-16 and 2a'	S12
I)	References	S14
J)	NMR Spectra	S15
K)	1D-nOe Spectra of compound 13a	S46
L)	HPLC Chromatograms	S49

A) General:

All reactions were conducted using oven-dried glassware under an atmosphere of Argon (Ar). Commercial grade reagents were used without further purification. Solvents were dried and distilled following usual protocols. Flash chromatography was carried out using silica gel (230-400 mesh). TLC was performed on aluminium-backed plates coated with silica gel 60 with F_{254} indicator.

The ¹H NMR spectra were recorded with a 200 and a 400 MHz and ¹³C NMR spectra were recorded with a 50 and a 100 MHz using CDCl₃, d₆-DMSO and CD₃OD. ¹H NMR chemical shifts are expressed in parts per million (δ) relative to CHCl₃ (d = 7.26), d₆-DMSO (δ = 2.48) and CD₃OD (δ = 3.34); ¹³C NMR chemical shifts are expressed in parts per million (δ) relative to the CDCl3 resonance (δ = 77.0), d₆-DMSO (δ = 40.1) and CD₃OD (δ = 49.2). Highresolution mass spectra (HRMS) were obtained under positive electron spray ionization (m/z values are given). HPLC analyses were done by Chiralpak IA column and IC column (4.6 mm × 250 mm and particle size 5µm and 3µm). Specific optical rotation values were measured on a Jasco-P1200 polarimeter. NOE experiment was done in 500 MHz NMR.

B) General procedure for the preparation of 4-arylbut-3-enoic acid:

(2-carboxyethyl)triphenylphosphonium bromide (1.2 eq) was suspended in dry THF. Aryl aldehyde (1 eq) was added. The mixture was cooled to -78 0 C, then a solution of ^{*t*}BuOK (2.5 eq) in dry THF was added continuously over 2 h. The reaction was stirred for 12-18 h during which it was allowed to warm to RT. The reaction was monitored by TLC analysis and after completion of the reaction THF was evaporated. 100 mL H₂O and 100 mL DCM was added. Aqueous layer was separated and acidified with 1(N) HCl up to pH=1. 100 ml Et₂O was added. The layers were separated and the aqueous layer was extracted with Et₂O (2 x100 mL). The combined organic layers were dried over Na₂SO₄ and the solvent was removed in vacuum (40 0 C). After flash chromatography on silica gel with hexane/EtOAc (3:1) 4-arylbut-3-enoic acids were obtained as a yellow solid (yield 50-65%).

C) General procedure for the preparation of tert-butyl 4-arylbut-3-enoate¹:

In a two-necked flask equipped with a magnetic stirring bar, anhydrous MgCl₂ (0.10 eq), BOC₂O (1.3 eq) and 4-arylbut-3-enoic acid (1.0 eq) were dissolved in ^tBuOH (2.0eq). The mixture was stirred at 40 ^oC and for 2-3 days and monitored by TLC analysis. The crude reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (3 x 10 mL). The organic layer was separated, dried (MgSO₄) and filtered, and the solvent was removed by rotary evaporation. The crude mixture was then subjected for column chromatography on silica gel with light petroleum ether/Et₂O (9:1). The *tert*-butyl 4-arylbut-3-enoate esters **1a-g** were obtained as light yellow oil (yield 85-95%).

D) General procedure for the preparation of (*E*)-*tert*-butyl 5-arylpent-4-enoate²:

To a heat-dried two-necked round-bottomed flask were added freshly distilled diisopropylamine (1.05 eq) and dry THF under argon. This solution was cooled to -78 °C, and n-BuLi (2.5 M in hexane, 1.05 eq) was then added via syringe. The mixture was stirred for 45 min, followed by addition of tert-butyl acetate (1 eq). The reaction mixture was stirred for 1 h. The resulting ester enolate-solution was was slowly added at -78 °C to the solution of bromide (1 eq) in THF via syringe. After stirring for 4 h at -78 °C the reaction mixture was quenched by addition of saturated NH₄Cl solution and allowed to warm up to room temperature. Then THF was evaporated and the aqueous layer was extracted with EtOAc. The combined extractes were dried over anhydrous MgSO₄, and concentrated under reduced

pressure. Flash chromatography on silica gel eluting with light petroleum ether/Et₂O (9:1) furnished (*E*)-tert-butyl 5-arylpent-4-enoate esters **5a-b** light yellow oil (yield 70-75%).

Aziridine reagents PhINSO₂(4-NO₂-C₆H₄) [PhINNs] were prepared by literature procedure.³

C2-symmetric bis-oxazoline ligands **4a-g** were synthesized by following literature procedure.⁴

E) General Procedure for one-pot enantioselective Synthesis of *N*-nosyl-4-amino-5arylbutyrolactones and *N*-nosyl-5-amino-6-arylvalerolactones ⁵ (3a-g, 10, 7a-b):

A 10 mL two-necked round bottom flask was charged with bis-oxazoline ligand **4g** (0.010g, 0.0279 mmol, 0.12 equiv), Cu(OTf)₂ (0.009 g, 0.0248 mmol, 0.10 equiv) and 0.2 g of powdered molecular sieves (4Å). Anhydrous chloroform (1.2 mL) was injected and the resulting mixture was stirred for 30 min at rt. Then the reaction mixture was placed at 40° C and to this solution, substrate **1** (0.389 g, 1.23 mmol, 5.0 equiv) in 1.2 mL chloroform, PhINNs (0.100 g, 0.247 mmol, 1.0 equiv) were added and the reaction mixture was allowed to stir at 40 °C under an argon atmosphere. As soon as all the nitrenoid reagent dissolved in the reaction medium, an additional amount of Cu(OTf)₂ (0.005 g, 0.0138 mmol) or ~ 0.2 g of silica gel (60-120 mesh) was added. On completion, the reaction was quenched by diluting with ethyl acetate (10 mL) and filtering through a short plug of silica gel. The silica gel was washed with additional 10 mL of ethyl acetate. The filtrate was concentrated by rotary evaporation under reduced pressure. The crude mass was subjected to purification by flash column chromatography using EtOAc/hexane as an eluent, which provided pure arylbutyrolactones and arylvalerolactones.

F) Spectral Data of *N*-nosyl-4-amino-5-arylbutyrolactones and *N*-nosyl-5-amino-6-arylvalerolactones (3a-i, 10, 7a-d and 13a-d):

4-nitro-*N*-((2*S*, 3*R*)-5-oxo-2-phenyltetrahydrofuran-3-yl)benzenesulfonamide(3a): White solid (0.072 g; 80%). M.p. 158-160 °C. FTIR (KBr, cm⁻¹): 3369, 2949, 2838, 1652, 1453, 1415, 1113, 1021. ¹H NMR (CDCl₃, 200 MHz): δ 8.22 (d, *J* = 8.8 Hz, 2H), 7.88 (d, *J* = 8.8 Hz, 2H), 7.41-7.30 (m, 3H), 7.20-7.16 (m, 2H), 5.58 (d, *J* = 8.2 Hz, 1H), 5.27 (d, *J* = 4.8 Hz, 1H), 4.16-4.12 (m, 1H), 3.04-2.92 (dd, *J* = 7.4, 17.4 Hz, 1H), 2.56-2.44 (dd, *J* = 6, 17.8 Hz,

1H). ¹³**C NMR** (CDCl₃, 50 MHz): δ 173.0 (C=O), 150.7, 147.2, 140.1, 128.5(2C), 128.1(2C), 127.3(2C), 125.2(2C), 123.6, 84.4, 59.6, 30.9. $[\alpha]_D{}^{32} = -5.42$ (c 0.1, Me₂CO) for 87% ee (**HPLC:** Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 15.06 min and minor 10.71 min). HRMS (ESI) calcd for C₁₆H₁₄N₂O₆NaS 385.0470, m/z [M+Na]⁺, found 385.0484.

N-((2*S*, 3*R*)-2-(4-fluorophenyl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzenesulfonamide (3b): White solid (0.059 g; 63%). M.p. 134-136 °C. FTIR (KBr, cm⁻¹): 3400, 2950, 2840, 1651, 1453, 1412, 1113, 1021. ¹H NMR (d₆-DMSO, 200 MHz): δ 8.94 (d, *J* = 7.2 Hz, 1H), 8.29 (d, *J* = 8.6 Hz, 2H), 7.86 (d, *J* = 8.6 Hz, 2H), 7.49-7.40 (m, 2H), 7.29-7.23 (m, 2H), 5.29 (d, *J* = 4.4 Hz, 1H), 4.32-4.29 (m, 1H), 2.99-2.84 (dd, *J* = 6.8, 17.4 Hz, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 175.7 (C=O), 162.2 (d, ¹*J*_{C,F} = 242.9 Hz), 150.0, 146.8, 134.5, 128.7 (d, ³*J*_{C,F} = 8.3 Hz), 128.2 (2C), 125.1 (2C), 116.1 (d, ²*J*_{C,F} = 21.4 Hz), 87.4, 56.9, 37.5. [α]_D³² = -11.36 (c 0.1, Me₂CO) for 90% ee (HPLC: Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 18.88 min and minor 12.92 min). HRMS (ESI) calcd for C₁₆H₁₃FN₂O₆NaS 403.0376, m/z [M+Na]⁺, found 403.0389.

N-((2*S*, 3*R*)-2-(4-chlorophenyl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzenesulfonamide (3c): White solid (0.067 g; 68%). M.p. 146-148 °C. FTIR (KBr, cm⁻¹): 3391, 2952, 2839, 1648, 1453, 1411, 1111, 1051, 1015. ¹H NMR (d₆-DMSO, 200 MHz): δ 8.92 (d, *J* = 6.8 Hz, NH), 8.21 (d, *J* = 8.6 Hz, 2H), 7.79 (d, *J* = 8.6 Hz, 2H), 7.45-7.26 (m, 4H), 5.10 (d, *J* = 7.2 Hz, 1H), 4.26-4.14 (m, 1H), 2.81-2.69 (dd, *J* = 7.2, 17 Hz, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 173.5 (C=O), 149.9, 146.5, 137.2, 134.1(2C), 129.4 (2C), 128.9, 128.4 (2C), 125.0 (2C), 83.4, 56.9, 37.2. [α]_D³² = -8.79 (c 0.09, Me₂CO) for 86% ee (HPLC: Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 17.68 min and minor 10.23 min). HRMS (ESI) calcd for C₁₆H₁₂ClN₂O₆S 395.0105, m/z [M-H]⁻, found 395.0109.

N-((2*S*, 3*R*)-2-(2-chlorophenyl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzenesulfonamide (3d): White solid (0.056 g; 57%). M.p. 122-124 °C. FTIR (KBr, cm⁻¹): 3437, 2952, 2841, 1647, 1452, 1410, 1151, 1112, 1017. ¹H NMR (d₆-DMSO, 200 MHz): δ 8.96 (d, *J* = 8.6 Hz, 1H), 8.25 (d, *J* = 8 Hz, 2H), 7.86 (d, *J* = 8 Hz, 2H), 7.55-7.38 (m, 4H), 5.50 (d, *J* = 6.6 Hz, 1H), 4.59-4.54 (m, 1H), 2.93-2.80 (dd, J = 7, 17.4 Hz, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 173.7 (C=O), 149.9, 146.4, 135.1, 133.9, 132.9, 131.1, 129.3, 128.1 (2C), 127.1, 124.9 (2C), 85.7, 56.3, 36.8. $[\alpha]_D^{32} = -9.92$ (c 0.1, Me₂CO) for 94% ee (**HPLC:** Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 9.90 min and minor 10.61 min). HRMS (ESI) calcd for C₁₆H₁₂ClN₂O₆S 395.0105, m/z [M-H]⁻, found 395.0097.

N-((2*S*, 3*R*)-2-(2-bromophenyl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzenesulfonamide (3e): White solid (0.061 g; 56%). M.p. 130-132 °C. FTIR (KBr, cm⁻¹): 3411, 2951, 2842, 1649, 1529, 1454, 1409, 1159, 1109, 1020. ¹H NMR (CDCl₃, 400 MHz): δ 8.20 (d, *J* = 8.8 Hz, 2H), 7.91 (d, *J* = 8.4 Hz, 2H), 7.39-7.16 (m, 4H), 5.50 (d, *J* = 4.8 Hz, 1H), 4.56 (d, *J* = 5.6 Hz, 1H), 4.09-4.08 (m, 1H), 2.89-2.83 (dd, *J* = 7.6, 17.6 Hz, 1H), 2.78-2.72 (dd, *J* = 6, 17.6 Hz, 1H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 173.8 (C=O), 150.1, 146.6, 135.6, 133.6, 131.6, 131.0, 129.7, 128.8 (2C), 127.5, 125.2 (2C), 83.4, 55.9, 35.8. [α]_D³² = -6.65 (c 0.09, Me₂CO) for 80% ee (HPLC: Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 9.72 min and minor 10.74 min). HRMS (ESI) calcd for C₁₆H₁₂BrN₂O₆S 438.9599, m/z [M-H]⁻, found 438.9608.

N-((2*S*, 3*R*)-2-(3-bromophenyl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzenesulfonamide (3*f*): White solid (0.068 g; 62%). M.p. 168-170 °C. **FTIR** (KBr, cm⁻¹): 3400, 2950, 2842, 1653, 1454, 1412, 1114, 1020. ¹**H NMR** (d₆-DMSO, 200 MHz): δ 8.98 (s, NH), 8.28 (d, *J* = 7.2 Hz, 2H), 7.88 (d, *J* = 7.4 Hz, 2H), 7.54-7.37 (m, 3H), 7.31-7.24 (m, 1H), 5.50 (d, *J* = 6.2 Hz, 1H), 4.40 (m, 1H), 2.91-2.79 (dd, *J* = 8, 17.6 Hz, 2H). ¹³**C NMR** (d₆-DMSO, 100 MHz): δ 173.7 (C=O), 149.9, 146.4, 135.4, 133.4, 131.4, 129.6, 128.7, 128.3 (2C), 125.0 (2C), 123.4, 83.3, 55.7, 35.6. [α]_D³² = -4.94 (c 0.1, Me₂CO) for 82% ee (**HPLC**: Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 9.78 min and minor 10.47 min). HRMS (ESI) calcd for C₁₆H₁₃BrN₂O₆NaS 462.9575, m/z [M+Na]⁺, found 462.9575.

N-((2*S*, 3*R*)-2-(4-methoxyphenyl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzenesulfon amide (3g): White solid (0.084 g; 87%). M.p. 164-166 °C. FTIR (KBr, cm⁻¹): 3427, 2948, 2845, 1646, 1530, 1451, 1410, 1277, 1113, 1049, 1018. ¹H NMR (d₆-DMSO, 200 MHz): δ 8.86 (s, NH), 8.21 (d, *J* = 8.8 Hz, 2H), 7.79 (d, *J* = 8.6 Hz, 2H), 7.17 (d, *J* = 8.6 Hz, 2H), 6.77 (d, *J* = 6.8 Hz, 2H), 5.04 (d, *J* = 7.8 Hz, 1H), 4.25-4.21 (m, 1H), 3.73 (s, 3H), 2.88-2.75 (dd, J = 8.2, 17.6 Hz, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 173.8 (C=O), 160.3, 149.9, 146.7, 129.3 (2C), 128.4 (4C), 125.0 (2C), 114.4, 84.4, 56.9, 55.7, 36.5. $[\alpha]_D^{32} = -7.15$ (c 0.09, Me₂CO) for 77% ee (**HPLC:** Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 0.8 ml/min, 254 nm, major 27.06 min and minor 17.56 min). HRMS (ESI) calcd for C₁₇H₁₆N₂O₇NaS 415.0576, m/z [M+Na]⁺, found 415.0585.

4-nitro-*N*-((2*S*,3*R*)-5-oxo-2-(*p*-tolyl)tetrahydrofuran-3-yl)benzenesulfonamide (3h): White solid (0.077 g; 83%). M.p. 126-128 °C. FTIR (KBr, cm⁻¹): 3390, 2953, 2843, 1652, 1534, 1454, 1412, 1353, 1169, 1053. ¹H NMR (d₆-DMSO, 200 MHz): δ 8.66 (d, *J* = 8.6 Hz, NH), 8.26 (d, *J* = 8.6 Hz, 2H), 7.83 (d, *J* = 8.6 Hz, 2H), 7.00-6.87 (m, 4H), 5.47 (d, *J* = 8.8 Hz, 1H), 4.03-3.97 (m, 1H), 2.81-2.69 (dd, *J* = 7.0, 17.0 Hz, 2H), 2.19 (s, 3H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 171.8 (C=O), 149.8, 145.6, 139.0, 135.6, 129.4, 127.9, 127.9, 127.7, 124.3, 124.0, 84.4, 56.2, 36.2, 21.3. [α]_D³² = -7.33 (c 0.1, Me₂CO) for 88% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 13.04 min and minor 9.77 min). HRMS (ESI) calcd for C₁₇H₁₆N₂O₆NaS 399.0627, m/z [M+Na]⁺, found 399.0638.

N-((2*S*,3*R*)-2-(benzo[*d*][1,3]dioxol-5-yl)-5-oxotetrahydrofuran-3-yl)-4-nitrobenzene

sulfonamide (**3i**): Light yellow solid (0.082 g; 82%). M.p. 194-196 °C. **FTIR** (KBr, cm⁻¹): 3416, 2952, 2843, 1646, 1527, 1453, 1452, 1406, 1286, 1109, 1054, 1017. ¹H NMR (d₆-DMSO, 200 MHz): δ 8.84 (bs, NH), 8.23 (d, J = 8.8 Hz, 2H), 7.78 (d, J = 8.6 Hz, 2H), 6.73 (d, J = 8.0 Hz, 3H), 5.93 (s, 2H), 4.96 (d, J = 8.2 Hz, 1H), 4.22 (m, 1H), 2.84-2.71 (dd, J = 7.8, 16.8 Hz, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 173.6 (C=O), 149.9, 148.3, 147.8, 146.8, 130.3, 128.5, 124.9, 122.3, 108.6, 107.8, 101.9, 84.4, 56.8, 36.5. [α]_D³² = -9.81 (c 0.1, Me₂CO) for 85% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 17.69 min and minor 10.12 min). LCMS (ESI) m/z : 405.0 [M-H]⁺, 424.4 [M+NH₄]⁺.

4-nitro-*N*-((2*S*, 3*R*)-6-oxo-2-phenyltetrahydro-2*H*-pyran-3-yl)benzenesulfonamide (7a): White solid (0.078 g; 84%). M.p. 138-140 °C. FTIR (KBr, cm⁻¹): 3227, 2926, 2831, 1654, 1526, 1457, 1383, 1349, 1158, 1092, 1041. ¹H NMR (CDCl₃, 200 MHz): δ 8.09 (d, *J* = 8.6 Hz, 2H), 7.64 (d, *J* = 8.6 Hz, 2H), 7.23-7.04 (m, 5H), 5.03 (d, *J* = 7.8 Hz, 2H), 3.74-3.54 (m, 1H), 2.78-2.68 (m, 2H), 2.38-2.29 (m, 1H), 2.03-1.93 (m, 1H). ¹H NMR (d₆-DMSO, 200 MHz): δ 8.48 (s, NH), 8.11 (d, *J* = 8.8 Hz, 2H), 7.64 (d, *J* = 8.6 Hz, 2H), 7.23-7.04 (m, 5H), 5.04 (d, *J* = 9.2 Hz, 1H), 3.78-3.66 (m, 1H), 2.62 (t, *J* = 5.4, 8.8 Hz, 2H), 1.92-1.76 (m, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 170.4 (C=O), 149.8, 147.2, 137.8, 128.7 (2C), 128.3 (2C), 128.1 (2C), 126.8, 125.1(2C), 82.9, 52.8, 30.2, 28.5. $[\alpha]_D^{32} = -18.20$ (c 0.6, Me₂CO) for 89% ee (**HPLC:** Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 60/40, 1.0 ml/min, 254 nm, major 9.43 min and minor 10.52 min). HRMS (ESI) calcd for C₁₇H₁₆N₂O₆NaS 399.0627, m/z [M+Na]⁺, found 399.0628.

N-((2*S*, 3*R*)-2-(4-fluorophenyl)-6-oxotetrahydro-2*H*-pyran-3-yl)-4-nitrobenzenesulfon amide (7b): White solid (0.077 g; 79%). M.p. 102-104 °C. FTIR (KBr, cm⁻¹): 3413, 2967, 2844, 1646, 1534, 1455, 1412, 1168, 1113, 1016. ¹H NMR (d₆-DMSO, 200 MHz):): δ 8.54 (d, *J* = 8.6 Hz, NH), 8.18 (d, *J* = 7.4 Hz, 2H), 7.66 (d, *J* = 7.6 Hz, 2H), 7.38 (t, *J* = 7.6, 5.6 Hz, 2H), 6.92 (t, *J* = 8.6, 8 Hz, 2H), 5.06 (d, *J* = 9.6 Hz, 1H), 3.85-3.68 (m, 1H), 2.63 (t, *J* = 6, 5.6 Hz, 2H), 1.97-1.89 (m, 2H). ¹³C NMR (d₆-DMSO, 50 MHz): δ 170.8 (C=O), 162.4 (d, ¹*J*_{C,F} = 241.5 Hz), 149.4, 146.9, 135.3, 129.5 (d, ³*J*_{C,F} = 8 Hz), 127.9 (2C), 124.7 (2C), 115.4 (d, ²*J*_{C,F} = 20.5 Hz), 84.2, 52.7, 28.5, 26.6. $[\alpha]_D^{32} = -34.82$ (c 0.5, Me₂CO) for 92% ee (**HPLC:** Daicel Chiralpak IC(particle size 5µm), hexane/EtOAc = 60/40, 1.0 ml/min, 254 nm, major 13.66 min and minor 11.95 min). HRMS (ESI) calcd for C₁₇H₁₅FN₂O₆NaS 417.0533, m/z [M+Na]⁺, found 417.0546.

N-((2*S*, 3*R*)-2-(4-chlorophenyl)-6-oxotetrahydro-2*H*-pyran-3-yl)-4-nitrobenzenesulfon amide (7c): White solid (0.078 g; 77%). M.p. 131-133 °C. FTIR (KBr, cm⁻¹): 3388, 2950, 2838, 1654, 1534, 1451, 1412, 1169, 1112, 1020. ¹H NMR (d₆-DMSO, 200 MHz):): δ 8.62 (d, *J* = 8.8 Hz, NH), 8.21 (d, *J* = 8.8 Hz, 2H), 7.67 (d, *J* = 8.8 Hz, 2H), 7.25-7.13 (m, 4H), 5.09 (d, *J* = 9.8 Hz, 1H), 3.87-3.65 (m, 1H), 2.71 (t, *J* = 7.2, 6.6 Hz, 2H), 2.03-1.93 (m, 2H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 170.4 (C=O), 149.5, 147.1, 136.9, 134.1, 129.8, 128.5, 128.1, 124.8, 81.7, 55.4, 28.7, 27.7. [α]_D³² = -22.73 (c 0.5, Me₂CO) for 84% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 14.05 min and minor 19.95 min). HRMS (ESI) calcd for C₁₇H₁₅ClN₂O₆NS 410.0339, m/z [M]⁺, found 410.0317.

N-((2*S*, 3*R*)-2-(2-bromophenyl)-6-oxotetrahydro-2*H*-pyran-3-yl)-4-nitrobenzenesulfon amide (7d): White solid (0.082 g; 73%). M.p. 162-164 °C. FTIR (KBr, cm⁻¹): 3408, 2950, 2842, 1647, 1531, 1452, 1413, 1162, 1019. ¹H NMR (d₆-DMSO, 400 MHz):): δ 8.61 (d, *J* = 8.8 Hz, NH), 8.22 (d, *J* = 8.8 Hz, 2H), 7.79 (d, *J* = 8.8 Hz, 2H), 7.46-7.37 (m, 2H), 7.29-7.26 (m, 1H), 7.17-7.13 (m, 1H), 5.43 (d, *J* = 9.2 Hz, 1H), 4.00-3.92 (m, 1H), 2.66 (t, *J* = 6.8, 7.2 Hz, 2H), 1.97-1.89 (m, 1H), 1.87-1.78 (m, 1H). ¹³C NMR (d₆-DMSO, 100 MHz): δ 169.8 (C=O), 149.8, 147.0, 136.4, 133.3, 130.9, 130.6, 128.3, 128.2, 124.9, 123.3, 81.9, 51.5, 28.3, 26.0. [α]_D³² = -21.80 (c 0.5, Me₂CO) for 88% ee (**HPLC:** Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 11.29 min and minor 12.00 min). LCMS (ESI) m/z : 454.9 [M+H]⁺, 472.4 [M+NH₄]⁺.

4-nitro-*N*-((*R*)-**1**-((**S**)-**3**-oxo-**1**, **3**-dihydroisobenzofuran-**1**-yl)propyl)benzenesulfonamide (**10**): Light Yellow solid (0.070 g; 75%). M.p. 228-230 °C. **FTIR** (KBr, cm⁻¹): 3385, 2951, 2835, 1654, 1455, 1420, 1113, 1023. ¹H NMR (CDCl₃, 400 MHz): δ 8.32 (d, *J* = 8.4 Hz, 2H), 8.04 (d, *J* = 8.4 Hz, 2H), 8.00-7.97 (m, 1H), 7.69-7.65 (m, 1H), 7.59-7.46 (m, 2H), 5.40 (d, *J* = 4.8 Hz, 1H), 4.64-4.61 (m, 1H), 3.89-3.84 (m, 1H), 1.69-1.46 (m, 2H), 0.94 (t, *J* = 7.2,7.6 Hz, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ 170.7 (C=O), 163.7, 149.9, 146.9, 136.2, 134.5, 130.4, 129.7, 128.8, 128.4(2C), 124.3 (2C), 83.8, 52.6, 29.6, 25.7. [α]_D³² = -22.65 (c 0.2, Me₂CO) for 79% ee (**HPLC**: Daicel Chiralpak IA(particle size 5µm), hexane/EtOAc = 65/35, 1.0 ml/min, 254 nm, major 15.02 min and minor 11.17 min). HRMS (ESI) calcd for C₁₇H₁₆N₂O₆NaS 399.0627, m/z [M+Na]⁺, found 399.0624.

(3*R*,5*R*,6*S*)-*tert*-butyl 3-methyl-5-(4-nitrophenylsulfonamido)-2-oxo-6-phenyltetrahydro-2*H*-pyran-3-carboxylate (13a): White solid (0.103 g; 85%). M.p. 160-162 °C. FTIR (KBr, cm⁻¹): 3434, 2952, 2842, 1647, 1532, 1452, 1406, 1163, 1113, 1052, 1017. ¹H NMR (CDCl₃, 200 MHz): δ 7.99 (d, *J* = 8.2 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.08 (s, 5H), 4.91-4.86 (m, 1H & NH), 3.91-3.88 (m, 1H), 2.71 (d, *J* = 12.8 Hz, 1H), 1.97 (t, *J* = 13.0, 13.8 Hz, 1H), 1.58 (s, 9H), 1.54 (s, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ 170.6 (C=O), 169.1 (C=O), 149.9, 145.2, 136.2, 129.6, 128.9, 127.9, 127.4, 124.3, 84.9, 84.2, 52.3, 51.7, 40.5, 28.0, 23.1. $[\alpha]_D^{32}$ = -61.32 (c 0.5, Me₂CO) for 90% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 7.74 min and minor 8.53 min). HRMS (ESI) calcd for C₂₃H₂₆N₂O₈NaS 513.1308, m/z [M+Na]⁺, found 513.1320.

(3R,5R,6S)-tert-butyl3-methyl-5-(4-nitrophenylsulfonamido)-2-oxo-6-(p-tolyl)tetrahydro-2H-pyran-3-carboxylate (13b):White solid (0.109 g; 87%).M.p. 132-134 °C.(KBr, cm⁻¹):3392, 2948, 2836, 1653, 1453, 1413, 1114, 1032.¹H NMR (CDCl₃, 200 MHz): δ 8.04 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 9.0 Hz, 2H), 6.99-6.88 (m, 4H), 4.85 (d, J = 10.4 Hz,1H), 4.69 (d, J = 7.2 Hz, 1H), 3.87 (m, 1H), 2.81-2.72 (dd, J = 4.8, 14.4 Hz, 1H), 2.28 (s,3H), 1.974 (t, J = 13, 14.4,1H), 1.59 (s, 9H), 1.56 (s, 3H).¹³C NMR (d_6-DMSO, 100 MHz): δ

171.2 (C=O), 161.1 (C=O), 149.8, 146.9, 138.8, 134.6, 129.3, 127.9, 127.8, 127.6, 125.1, 124.9, 83.8, 83.4, 51.0, 51.6, 28.1, 22.9, 21.1. $[\alpha]_D^{32} = -34.54$ (c 0.3, Me₂CO) for 96% ee (**HPLC:** Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 8.59 min and minor 10.23 min). HRMS (ESI) calcd for C₂₄H₂₈N₂O₈NaS 527.1464, m/z [M+Na]⁺, found 527.1472.

(*3R*,5*R*,6*S*)-*tert*-butyl 6-(4-fluorophenyl)-3-methyl-5-(4-nitrophenylsulfonamido)-2-oxo tetrahydro-2*H*-pyran-3-carboxylate (13c): White solid (0.102 g; 81%). M.p. 146-148 °C. FTIR (KBr, cm⁻¹): 3435, 2953, 2844, 1641, 1532, 1455, 1349, 1162, 1119, 1053, 1016. ¹H NMR (CDCl₃, 200 MHz):): δ 8.09 (d, *J* = 8.6 Hz, 2H), 7.53 (d, *J* = 8.8 Hz, 2H), 7.12-7.05 (m, 2H), 6.78 (t, *J* = 8.4, 8.6 Hz, 2H), 5.11 (d, *J* = 8.6 Hz, 1H), 4.91 (d, *J* = 10.4, 1H), 3.89-3.85 (m, 1H), 2.65-2.56 (dd, *J* = 3.4, 13.6, 1H),1.96 (t, *J* = 12.8, 13.0 Hz, 1H), 1.58 (s, 9H), 1.51 (s, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ 170.4 (C=O), 168.9 (C=O), 163.4 (d, ¹*J*_{C,F} = 266.4 Hz), 150.0, 145.6, 132.3, 129.3 (d, ³*J*_{C,F} = 8.4 Hz), 128.0 (2C), 124.3 (2C), 115.9 (d, ²*J*_{C,F} = 21.7 Hz), 84.3, 52.5, 51.8, 40.4, 28.1, 23.0. [α]_D³² = -66.32 (c 0.1, Me₂CO) for 98% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 7.56 min and minor 8.28 min). LCMS (ESI) m/z : 526.0 [M+NH₄]⁺.

(*3R*,5*R*,6*S*)-*tert*-butyl 6-(2-bromophenyl)-3-methyl-5-(4-nitrophenylsulfonamido)-2-oxo tetrahydro-2*H*-pyran-3-carboxylate (13d): White solid (0.111 g; 79%). M.p. 126-128 °C. FTIR (KBr, cm⁻¹): 3426, 2950, 2841, 1651, 1531, 1454, 1350, 1163, 1111, 1018. ¹H NMR (CDCl₃, 200 MHz): δ 7.98 (d, *J* = 8.0 Hz, 2H), 7.53 (d, *J* = 8.0 Hz, 2H), 7.29-7.26 (m, 1H), 7.21 (d, *J* = 8.0 Hz, 1H), 7.11 (t, *J* = 6.8, 7.6 Hz, 1H), 7.00 (t, *J* = 7.2, 7.6 Hz, 1H), 5.52 (d, *J* = 8.0 Hz, 1H), 5.09 (d, *J* = 4.4 Hz, 1H), 3.98 (bs, 1H), 2.70 (d, *J* = 11.2 Hz, 1H, 1H), 2.09 (m, 1H), 1.59 (s, 9H), 1.57 (s, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ 170.1 (C=O), 168.3 (C=O), 149.8, 145.1, 136.2, 132.5, 130.6, 128.8, 128.3, 127.5, 124.1, 123.1, 84.1, 81.7, 53.4, 51.6, 41.1, 27.9, 22.9. $[\alpha]_D^{32} = -94.19$ (c 0.7, Me₂CO) for 94% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/EtOAc = 50/50, 0.5 ml/min, 254 nm, major 7.58 min and minor 9.17 min). HRMS (ESI) calcd for C₂₃H₂₅BrN₂O₈NaS 591.0413, m/z [M+Na]⁺, found 591.0421.

G) Spectral Data of alkenoic acid esters (1a-i, 8, 5a-d, 11a-d and 1a'):

(*E*)-*tert*-butyl 4-phenylbut-3-enoate (1a): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.34-7.16 (m, 5H), 6.37 (d, J = 15.6 Hz, 1H), 6.25-6.10 (m, 1H), 3.05 (d, J = 6.8 Hz, 2H), 1.37 (s, 9H).

(*E*)-*tert*-butyl 4-(4-chlorophenyl)but-3-enoate (1c): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.41-7.23 (m, 4H), 6.42 (d, *J* = 16.4 Hz, 1H), 6.33-6.18 (m, 1H), 3.15 (d, *J* = 6.6 Hz, 2H), 1.46 (s, 9H).

(*E*)-*tert*-butyl 4-(4-fluorophenyl)but-3-enoate (1b): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.38-7.25 (m, 2H), 7.12-7.09 (m, 2H), 6.42 (d, *J* = 15.8 Hz, 1H), 6.26-6.12 (m, 1H), 3.14 (d, *J* = 7 Hz, 2H), 1.47 (s, 9H).

(*E*)-*tert*-butyl 4-(2-chlorophenyl)but-3-enoate (1d): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.39-7.15 (m, 4H), 6.85 (d, *J* = 16 Hz, 1H), 6.40-6.21 (m, 1H), 3.21 (d, *J* = 7 Hz, 2H), 1.48 (s, 9H).

(E)-tert-butyl 4-(2-bromophenyl)but-3-enoate (1e): Light yellow oil. ¹H NMR (CDCl₃, 400 MHz): δ 7.40-7.23 (m, 3H), 7.15-6.97 (m, 1H), 6.83 (d, J = 15.6 Hz, 1H), 6.34-6.24 (m, 1H), 3.24-3.22 (dd, J = 1.6, 7.2 Hz, 2H), 1.49 (s, 9H).

(*E*)-*tert*-butyl 4-(3-bromophenyl)but-3-enoate (1f): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.39-7.12 (m, 4H), 6.44-6.21 (m, 2H), 3.15 (d, *J* = 5.6 Hz, 2H), 1.47 (s, 9H).

(E)-tert-butyl 4-(4-methoxyphenyl)but-3-enoate (1g): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.30 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 6.41 (d, J = 15.8 Hz, 1H), 3.80 (s, 3H), 3.12 (d, J = 6.8 Hz, 2H), 1.46 (s, 9H).

(*E*)-*tert*-butyl 4-(*p*-tolyl)but-3-enoate (1h): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.30-7.10 (m, 4H), 6.45 (d, *J* = 15.8 Hz, 1H), 6.32-6.17 (m, 1H), 3.16 (d, *J* = 6.8 Hz, 2H), 2.34 (s, 3H), 1.48 (s, 9H).

(*E*)-*tert*-butyl 4-(benzo[*d*][1,3]dioxol-5-yl)but-3-enoate (1i): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 6.93 (s, 1H), 6.88-6.72 (m, 2H), 6.38 (d, *J* = 16.0 Hz, 1H), 6.18-6.07 (m, 1H), 5.92 (s, 2H), 3.13 (d, *J* = 7.0 Hz, 2H), 1.47 (s, 9H).

tert-butyl 2-(but-1-en-1-yl)benzoate (8): *E* :*Z* = 82 : 18. Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.84 (d, *J* = 7.4 Hz, 0.22H), 7.75 (d, *J* = 7.8 Hz, 1H), 7.52-7.19 (m, 3.66H), 7.05 (d, *J* = 15.6 Hz, 1H), 6.77 (d, *J* = 11.6 Hz, 0.22H), 6.21-6.07 (m, 1H), 5.75-5.39 (m, 0.22H), 2.30-2.09 (m, 2.44H), 1.59 (s, 9H), 1.14 (t, *J* = 7.4, 7.4 Hz, 3H), 1.03 (t, *J* = 7.4, 7.4 Hz, 0.66H).

(*E*)-*tert*-butyl 5-phenylpent-4-enoate (5a): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.35-7.16 (m, 5H), 6.42 (d, *J* = 15.8 Hz, 1H), 6.27-6.16 (m, 1H), 2.51-2.34 (m, 4H), 1.45 (s, 9H).

(E)-tert-butyl 5-(4-fluorophenyl)pent-4-enoate (5b): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.33-7.24 (m, 2H), 7.08-6.92 (m, 2H), 6.38 (d, J = 15.6 Hz, 1H), 6.17-6.03 (m, 1H), 2.50-2.33 (m, 4H), 1.44 (s, 9H).

(*E*)-*tert*-butyl 5-(4-chlorophenyl)pent-4-enoate (5c): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.39-7.25 (m, 4H), 6.38 (d, *J* = 15.8 Hz, 1H), 6.25-6.14 (m, 1H), 2.55-2.35 (m, 4H), 1.45 (s, 9H).

(*E*)-*tert*-butyl 5-(2-bromophenyl)pent-4-enoate (5d): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.55-7.46 (m, 2H), 7.28-7.21 (m, 1H), 7.11-7.03 (m, 1H), 6.76 (d, *J* = 15.6 Hz, 1H), 6.24-6.09 (m, 1H), 2.56-2.43 (m, 4H), 1.47 (s, 9H).

di*-tert*-**butyl 2-cinnamyl-2-methylmalonate** (**11a**): Light yellow oil. ¹**H NMR** (CDCl₃, 200 MHz): δ 7.32-7.23 (m, 5H), 6.45 (d, *J* = 15.8 Hz, 1H), 6.19-6.05 (m, 1H), 2.69 (d, *J* = 7.4 Hz, 2H), 1.46 (s, 9H), 1.37 (s, 3H).

(*E*)-di-*tert*-butyl 2-(3-(2-bromophenyl)allyl)-2-methylmalonate (11d): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.50 (t, *J* = 7.8, 11 Hz, 2H), 7.24-7.21 (m, 1H), 7.11-7.04 (m, 1H), 6.79 (d, *J* = 15.6 Hz, 1H), 6.16-6.00 (m, 1H), 2.74 (d, *J* = 7.6 Hz, 2H), 1.46 (s, 9H), 1.38 (s, 3H).

(*E*)-di-*tert*-butyl 2-methyl-2-(3-(*p*-tolyl)allyl)malonate (11c): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.30-7.15 (m, 4H), 6.44 (d, *J* = 15.8 Hz, 1H), 6.16-6.01 (m, 1H), 2.70 (d, *J* = 7.4 Hz, 2H), 2.36 (s, 3H), 1.49 (s, 9H), 1.39 (s, 3H).

(*E*)-di-*tert*-butyl 2-(3-(4-fluorophenyl)allyl)-2-methylmalonate (11b): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.35-7.28 (m, 2H), 7.01 (t, *J* = 8.8, 8.6 Hz, 2H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.14-5.99 (m, 1H), 2.70 (d, *J* = 7.0 Hz, 2H), 1.49 (s, 9H), 1.39 (s, 3H).

(*E*)-methyl 4-phenylbut-3-enoate (1a'): Light yellow oil. ¹H NMR (CDCl₃, 200 MHz): δ 7.49-7.24 (m, 5H), 6.51 (d, *J* = 15.8 Hz, 1H), 6.38-6.23 (m, 1H), 3.73 (s, 3H), 3.29 (d, *J* = 6.8 Hz, 2H).

H) Synthesis and Spectral Data of compounds 14-16 and 2a':

(4*R*, 5*S*)-4-amino-5-(4-methoxyphenyl)dihydrofuran-2(3*H*)-one (14):To a well stirred solution of 3g (0.16 g, 0.408 mmol) taken in 3 mL CH₃CN:DMSO (49:1) at rt, 1.1 equiv 4-methoxythiophenol (0.055mL, 0.449 mmol) and 1.1 equiv of K_2CO_3 (0.62 g, 0.449 mmol) were added and the reaction mixture was allowed to stir for 4 h. Upon completion of the reaction the reaction mixture was filtered using MeOH as an eluent. Solvent was evaporated under reduced pressure and the crude yellow oil was immediately used in the next step.

tert-butyl ((2*S*, 3*R*)-2-(4-methoxyphenyl)-5-oxotetrahydrofuran-3-yl)carbamate (15): The crude yellow oil was taken in 10 mL dry THF. 3.3 equiv of BOC₂O (0.309 mL, 1.346 mmol) was added and the reaction mixture was allowed to stir for overnight. Solvent was evaporated under reduced pressure and 20 mL of EtOAc was added. The organic layer washed with H₂O (2 X 15 mL) and the dried over Na₂SO₄. Concentration and column chromatography (20% EtOAc in hexane) gave titled compound **15** as white solid (0.102 g, yield 82% in overall two steps). M.p. 112-114 °C. ¹H NMR (CDCl₃, 200 MHz): δ 7.35-7.27 (m, 2H), 6.95-6.90 (m, 2H), 5.41 (bs, NH), 4.91 (d, J = 5.6 Hz, 1H), 4.27 (m, 1H), 3.83 (s, 3H), 3.03-2.86 (dd, *J* = 7.8, 25.6 Hz, 1H), 2.55-2.44 (dd, *J* = 4.8, 17.8 Hz, 1H), 1.45 (s, 9H). ¹³C NMR (CDCl₃, 100 MHz): δ 173.5 (C=O), 159.9, 128.9 (2C), 126.8 (2C), 114.4, 86.1, 78.5, 56.6, 55.5, 34.4, 28.4. (*S*)-3-((*tert*-butoxycarbonyl)amino)-4-(4-methoxyphenyl)butanoic acid (16): Compound 15 (0.1 g, 0.16 mmol) was taken in 4 mL MeOH. After addition of 10% Pd-C (0.1 equiv), the reaction mixture was purged with H₂ and the reaction mixture was stirred under the H₂ atmosphere for 1.5 h. On completion, the mixture was passed through a celite pad, washed with MeOH (3 x 20 mL), on solvent evaporation pure compound 16 was obtained as a colourless solid (0.097 g, yield 96%). M.p. 102-104 °C. ¹H NMR (CD₃OD, 200 MHz): δ 7.12 (d, *J* = 8.2 Hz, 2H), 6.83 (d, *J* = 8 Hz, 2H), 4.11-4.04 (m, 1H), 3.76 (s, 3H), 2.71(m, 2H), 2.48 (m, 2H), 1.37 (s, 9H). ¹³C NMR (CD₃OD, 50 MHz): δ 173.9 (C=O), 158.6, 156.6, 130.4, 130.2, 113.6, 78.8, 54.4, 41.6, 39.7, 27.8.⁶ [α]_D²⁶ = -17.4 (*c* 1.1, EtOH), [Lit⁷. [α]_D²⁰ = -18.7 (*c* 1, EtOH)].

methyl 2-((2*R*,3*R*)-1-((4-nitrophenyl)sulfnyl)-3-phenylazirdin-2-yl)acetate (2a'): White solid (0.054 g, 61% yield). M.p. 138-140 °C. ¹H NMR (CDCl₃, 200 MHz):): δ 8.26 (d, J = 8.6 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 7.22-7.02 (m, 5H), 4.09 (d, J = 3.8 Hz, 1H), 3.71 (s, 3H), 3.22-3.03 (m, 3H). ¹³C NMR (CDCl₃, 100 MHz): δ 171.9 (C=O), 151.0, 147.1, 141.3, 135.5, 128.6, 128.4, 127.6, 126.3, 54.7, 52.2, 50.9, 38.3. $[\alpha]_D^{32} = -12.11$ (c 0.18, Me₂CO) for 72% ee (HPLC: Daicel Chiralpak IA(particle size 3µm), hexane/^{*i*}PrOH = 85/15, 1.0 ml/min, 254 nm, major 13.56 min and minor 9.58 min).

I) References:

1. G. Bartoli, M. Bosco, A. Carlone, R. Dalpozzo, E. Marcantoni, P. Melchiorre, L. Sambri, *Synthesis*, 2007, 3489.

2. R. Sanz, J. M. Ignacio, M. A. Rodriguez, F. J. Fananas, J. Barluenga, *Chem. Eur. J.*, 2007, **13**, 4998.

3. D. Ryan, P. McMorn, D. Bethell, G. Hutchings, Org. Biomol. Chem., 2004, 2, 3566.

4. A. Cornejo, J. M. Fraile, J. I. Garcia, M. J. Gil, V. Martinez-Merino, J. A. Mayoral, E. Pires, I. Villalba, *Synlett.*, 2005, **15**, 2321.

5. S. Hajra, B. Maji and D. Mal, *Adv. Synth. Catal.*, 2009, **351**, 859; Corrigendum: S. Hajra,
B. Maji and D. Mal, *Adv. Synth. Catal.*, 2010, **352**, 3112; DOI: 10.1002/adsc.201090036.

6. L. M. Dedkova, N. E. Fahmi, R. Paul, M. del Rosario, L. Zhang, S. Chen, G. Feder, S. M. Hecht, *Biochemistry*, 2012, **51**, 401.

7. L. Lankiewicz, D. Glanz, Z. Grzonka, J. Slaninova, T. Barth, F. Fahrenholz, *Bulletin of the Polish Academy of Sciences, Chemistry*, 1989, **37**, 45.





 ^{13}C NMR of compound 3c (100 MHz, d_6-DMSO)















¹H NMR of compound **1a** (200 MHz, CDCl₃)

¹H NMR of compound **1b** (200 MHz, CDCl₃)

 1 H NMR of compound **1g** (200 MHz, CDCl₃)




 1 H NMR of compound **5a** (200 MHz, CDCl₃)















K) 1D-nOe Spectra of compound 13a:



 1 H NMR of compound **13a** (500 MHz, CDCl₃)



1D-nOe spectrum of compound 13a (SR at 3.887ppm, 500 MHz, CDCl₃)



1D-nOe spectrum of compound 13a (SR at 1.515ppm, 500 MHz, CDCl₃)

L) HPLC Chromatograms:



HPLC Chromatogram of compound 3a



HPLC Chromatogram of compound $(\pm)3a$









HPLC Chromatogram of compound (±)3c

HPLC Chromatogram of compound 3b



HPLC Chromatogram of compound (±)3b



S54







HPLC Chromatogram of compound $(\pm) 3e$







HPLC Chromatogram of compound (±)3f



HPLC Chromatogram of compound 3g



HPLC Chromatogram of compound (±)3g



HPLC Chromatogram of compound 3h



HPLC Chromatogram of compound (±)3h



HPLC Chromatogram of compound 3i



HPLC Chromatogram of compound (±)3i



HPLC Chromatogram of compound ${\bf 10}$



HPLC Chromatogram of compound (±)10



HPLC Chromatogram of compound 7a



HPLC Chromatogram of compound (±)7a



HPLC Chromatogram of compound 7b



HPLC Chromatogram of compound (±)7b



HPLC Chromatogram of compound 7c



HPLC Chromatogram of compound (±)7c


HPLC Chromatogram of compound 7d



HPLC Chromatogram of compound (±)7d



HPLC Chromatogram of compound 13a







HPLC Chromatogram of compound 13c



HPLC Chromatogram of compound (±)13c



HPLC Chromatogram of compound 13b



HPLC Chromatogram of compound (±)13b



HPLC Chromatogram of compound 13d







HPLC Chromatogram of compound 2a'

